Woden client Neurent Medical has secured a $74 million Series C investment led by MVM Partners to accelerate the commercial expansion of its NEUROMARK® technology.
NEUROMARK is a proprietary technology that enables physicians to target and safely disrupt nerve branches to alleviate symptoms and improve patient quality of life.
CEO and founder Brian Shields engaged Woden to uncover how to effectively translate their technical capabilities into a story that resonates with the rhinologists.
Through the StoryKernel, Woden developed a narrative strategy that centered physicians as the heroes of the story, positioning NEUROMARK an essential part of their practice. While the industry often focuses on technical disruption, the narrative uncovered that Neurent Medical’s greatest ability was to strengthen the relationship between patient and physician.
Woden developed a StoryGuide to help Neurent Medical translate this reality for the market: to ensure every ENT can deliver a treatment experience that amplifies their unique expertise while fostering deeper patient trust.
With this new funding, Neurent Medical is accelerating its commitment to the expansion of treating Chronic Rhinitis and staying at the forefront of medical innovation.
